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these findings require further confirmation to establish the role of NAC in 
improving reproductive outcomes in women with PCOS.  
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OBJECTIVES: Recent literature suggests an increased risk of diabetes following 
smoking cessation. Our objective was to compare the risk of developing diabetes 
among obese smokers using bupropion versus varenicline as well as other 
predictors during the first 3 years post-cessation. METHODS: A population-based 
retrospective cohort study was conducted using the General Electric (GE) 
electronic medical record database (2006 – 2011). The cohort consisted of obese 
adult smokers newly initiating use of a smoking cessation medication: 
bupropion versus varenicline without a diabetes diagnosis at baseline. The 
outcome variable was time to developing diabetes following first prescription 
with a 3-year follow up. Chi-square tests were conducted to assess the frequency 
distribution of sample characteristics and association with diabetes 
development. Univariate survival analyses using Kaplan-Meier survival curve 
were conducted and log-rank test was used to assess significance. Cox 
Proportional Hazard (PH) regression model was carried out after evaluating PH 
assumption by Schoenfeld residual test. Interaction terms were included in the 
PH regression model if assumption was violated. RESULTS: The sample 
comprised of 91,899 individuals. A total of 3,668 (crude diabetes incidence rate: 
13.3 per 1,000 person-years) obese smokers developed diabetes in 3 years. 
Abstinence at 12 months did not meet the PH assumption and interaction was 
created for this variable in the final Cox model. There was no statistically 
significant difference in diabetes risk using bupropion versus varenicline (Hazard 
Ratio: 1.408 95% Confidence Interval: 0.963 - 2.058). Non-primary care group 
(1.271 [1.069 – 1.511]), male (1.174 [1.004 – 1.373]), non-white (1.197 [1.015 – 1.410]), 
age group (40 – 64) (0.803 [0.656 – 0.984]), abstinence at 12 months (0.758 [0.604 – 
0.952]), hypertension (1.239 [1.017 – 1.509]),and lung cancer (2.023 [1.024 – 3.999]) 
were significant predictors of developing diabetes. CONCLUSIONS: There is no 
significant difference in the diabetes risk three years post-cessation among 
obese adults using varenicline versus bupropion.  
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OBJECTIVES: Both biphasic human insulin 30 (BHI30) and biphasic insulin aspart 
(BIAsp30) serve an effective treatment option in patients with T2DM and their 
relative efficacy has been investigated in randomized clinical trials (RCTs). The 
aim of our analysis was to compare efficacy and safety of BIAsp30 with BHI30 on 
the basis of non-interventional trials. METHODS: Systematic search in PubMed, 
Medline and CENTRAL was carried out until November 2011. Non-interventional 
trials comparing either BIAsp30 with BHI30 in a parallel design or assessing a 
replacement therapy with one insulin preparation after suboptimal response to 
the other were included. RESULTS: Eight studies met the inclusion criteria; three 
compared directly BIAsp30 with BHI30, five assessed BIAsp30 after suboptimal 
treatment with BHI30. No studies evaluating BHI30 after BIAsp30 were identified. 
Meta-analysis of parallel studies demonstrated superiority of BIAsp30 over BHI30 
with respect to the reduction of HbA1c (3 studies; WMD = -0.16% [-0.24; -0.08]) 
without increased risk of hypoglycemic episodes. Switching from BHI30 to 
BIAsp30 was associated with noticeable improvement in HbA1c level (3 studies; 
WMD = -1.69% [-1.94; -1.45]), fasting glucose (2 studies; -3.20 mmol/l [-3.75; -2.65]) 
and post-prandial glucose level (2 studies; WMD = -4.66 mmol/l [-4.74; -4.58]). The 
largest study demonstrated that the use of BIAsp30 instead of BHI30 revealed 
statistically significant reduction in the incidence of both minor (MD = -5.7 
episodes/patient/year; p<0.0001) and major hypoglycemic episodes (MD = -0.331; 
p<0.0001). BIAsp 30 was not associated with a weight gain either in parallel 
design nor in studies assessing sequential treatment. CONCLUSIONS: In this 
analysis, including real clinical practice studies BIAsp30 was more effective than 
BHI30 in the control of T2DM. Additionally, BIAsp30 was a good alternative for 
patients with failure or suboptimal response to previous insulin therapy with 
BHI30.  
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OBJECTIVES: The goal of the “Diabetes Peer to Peer (P2P®) Study” was to assess 
the effect of social networks for diabetes information sharing on the 
improvement of diabetes management in patients with type 2 diabetes in the 
Baltimore metropolitan area. METHODS: In this prospective cohort study 
enrolling patients with diabetes, those in the intervention group (P2P®) were 
asked to recruit peers, form small groups, and attend monthly diabetes 
education sessions, emphasizing peer-support. Patients in the control group 
were recruited individually to attend standard diabetes education sessions. The 
primary outcomes were changes in Hemoglobin A1C (HbA1c) and blood glucose. 
Secondary outcomes included clinical indicators (blood pressure, BMI), 
functional status, self-efficacy, perceived cohesion, social network 
connectedness, and diabetes knowledge. Socio-demographics, drug history, and 
comorbidities were also recorded. Multivariate regression models, finalized after 
a stepwise selection process, were built to assess mean absolute changes in 
HbA1c and blood glucose at the first follow-up, at three months. RESULTS: Of a 
total of 136 enrolled, the intervention patients (68) had more metformin use, 
higher BMI, lower social network scores, and lower diabetes knowledge at 
baseline. All other baseline characteristics were evenly distributed between 
arms. At follow-up, P2P® patients had a larger reduction in HbA1c (-0.47 vs.  
-0.31%, P=0.17) and blood glucose (-9.1 vs. -2.4 mg/dL, P=0.05) than the controls. 
In multivariate adjusted models, P2P® was associated with a statistically 
significantly larger mean reduction in HbA1c (-0.33%, P<0.01) and blood glucose (-
8.6 mg/dL, P<0.01), than the control. Marital status, insulin use, high baseline 
Hba1c, and good physical functional status were associated with a significant 
drop in Hba1c and blood glucose. CONCLUSIONS: The social networks, as 
opposed to the individual approach to diabetes education, prove more effective 
at reducing patients’ HbA1c and blood glucose at 3-months follow-up.  
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OBJECTIVES: To compare real-world outcomes among Medicaid patients with 
type 2 diabetes mellitus (T2DM) initiating insulin glargine (GLA) or insulin 
detemir (DET). METHODS: Using the MarketScan®Multi-State Medicaid claims 
database, this retrospective study examined T2DM patients aged ≥18 years who 
were previously insulin-naive and initiated GLA or DET between 2006 and 2009. 
All patients had continuous Medicaid coverage for ≥6 months before (baseline) 
and ≥12 months after GLA or DET initiation. Stringent propensity-score matching 
was used to balance DET with GLA patients, and a subgroup of disposable-pen 
users in both groups, on baseline characteristics. Endpoints included 1-year 
follow-up treatment persistence and adherence, hypoglycemia rates, and health 
care costs. RESULTS: Included in the main analysis were 1,354 DET users, 
matched with 1:up to 2 ratio to 2,573 GLA users from 11 states/health plans 
(mean age 53 years; 71% female). In the subanalysis of disposable-pen users, 548 
from each group were 1:1 matched (mean age 55 years; 70% female). Compared 
with DET users, GLA users were more treatment-persistent (main analysis 
[subanalysis]: 44.2% versus 47.2% [46.7% vs. 54.2%]; P=0.071 [P=0.015]), had more 
persistent days (257 vs. 266 [267 vs. 287] days; P=0.008 [P<0.001]), and were more 
adherent (adjusted medication possession ratio 61.1% vs. 65.0% [61.4% vs. 66.7%]; 
P<0.001 [P=0.006]). Hypoglycemia rates were similar for both groups (10.8% vs. 
10.7% [11.1% vs. 8.9%]; P=0.957 [P=0.225]). Det patients incurred higher diabetes-
related outpatient ($2,198 vs. $1,942 [$2,252 vs. $2,067]; P=0.038 [P=0.418]) and 
drug costs ($1,570 vs. $1,397 [$1,432 vs. $1,338]; P=0.002 [P=0.400]), although 
overall costs were similar ($20,371 vs. $21,210 [$15,847 vs. $15,883]; P=0.548 
[P=0.985]). CONCLUSIONS: This study suggests that initiating GLA in T2DM 
Medicaid patients was associated with better treatment persistence and 
adherence than DET. However, the findings are exploratory, limited by their 
retrospective nature and the lack of key clinical data such as A1C.  
 
PDB13  
A COHORT ASSESSMENT OF CHILDREN BORN SMALL FOR GESTATIONAL AGE 
OR WITH INTRAUTERINE GROWTH RETARDATION TREATED WITH GROWTH 
HORMONE IN COLOMBIA  
Ortiz Picon T1, Duran P2, Jaimes GC3, Mejia Zapata LM4, Manrique LA5, Suarez MB6, 
Gutierrez-Ardila MV7 
1Hospital Militar Central – Laboratorio de Investigación Hormonal, Bogota, Colombia, 2Fundacion 
Cardio Infantil, Bogota, Cundinamarca, Colombia, 3Hospital Militar Central, Bogota, 
Cundinamarca, Colombia, 4fundacion Clinica Valle del Lili - Fundacion Club Noel, Cali, Colombia, 
5Centro Médico Farallones, Cali, Valle, Colombia, 6Hospital Naval - Cirujanos y Pediatras 
Asociados, Barranquilla, Colombia, 7Pfizer S.A.S., Bogota, Colombia  
OBJECTIVES: To compare the outcomes of a cohort of children born small  
for gestational age and/or with intrauterine growth retardation (SGA/IUGR) 
treated with growth hormone (GH) in Colombia with a global cohort from KIGS 
(Pfizer International Growth Database) population of the same characteristics 
(Ranke et al, 2010), over 1 and 2 years. METHODS: Two Colombian children 
cohorts, diagnosed with SGA/IUGR and treated with GH, included in KIGS, were 
assessed: cohort 1 (n=39) with 1-year follow-up and cohort 2 (n=16) with 2-year 
follow-up. The cohort characteristics (clinical outcomes in Standard Deviation 
Score (SDS) for height, weight, body mass index, and growth rate [cm/year]) were 
described at the time of initiation of therapy and at 1 and 2 years follow-up,  
and were compared with children from the global cohort. RESULTS: Cohort 1 
began treatment at 6.63 years (average) with a height of -3.20 SDS and weight of -
2.42 SDS, growth rate reported after one year of treatment was 0.22cm lower 
than the global cohort (8.18 vs 8.4 cm/yr respectively); Cohort 2 with, began 
treatment at 5.28 years (average) with a height of -3.83 SDS and a weight of -3.73 
SDS; reported growth rate was 0.27 cm lower than the global cohort in the 1-year 
follow-up and 0.63 cm over the 2-year follow-up (8.23 vs. 8.5 and 7.63 vs. 7.00 
cm/year respectively). Regarding the height difference (SDS), cohort 1 was 0.12 
SDS lower than the global cohort (0.58 vs. 0.7) and cohort 2 was 0.2 SDS lower 
than the first year of follow-up and 0.05 SDS higher than the 2 year follow-up (0.5 
vs. 0.7 and 0.45 vs. 0.4, respectively). CONCLUSIONS: This analysis demonstrates 
that GH administration has a positive effect on height in children diagnosed 
SGA/IUGR in Colombia; they respond to therapy similarly to a globally treated 
cohort.  
